Back to top
more

Cerus (CERS)

(Real Time Quote from BATS)

$1.68 USD

1.68
1,270,739

-0.05 (-2.89%)

Updated Apr 16, 2024 09:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 40% and 2.76%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 0.61% and 0.51%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of -40% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cerus (CERS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of -80% and 1.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)

by Zacks Equity Research

Cerus (CERS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Down 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround

by Zacks Equity Research

Cerus (CERS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Cerus (CERS) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Cerus (CERS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts See an 89% Upside in Cerus (CERS): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at an 88.6% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Cerus (CERS) Have the Potential to Rally 88% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Cerus (CERS) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Cerus (CERS) Have the Potential to Rally 89% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Cerus (CERS) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 16.25% and 1.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Does Cerus (CERS) Have the Potential to Rally 90% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sumit Singh headshot

4 Growth Stocks Under $10 to Buy for 2022

by Sumit Singh

Growth stocks tend to perform well when the economy starts to pick up. Nissan Motor (NSANY), Arko Corp. (ARKO), Arcos Dorados (ARCO) and Cerus (CERS) look well-poised to grow.

How Much Upside is Left in Cerus (CERS)? Wall Street Analysts Think 44%

by Zacks Equity Research

The consensus price target hints at a 43.9% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Debanjana Dey headshot

3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022

by Debanjana Dey

Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.

Wall Street Analysts Think Cerus (CERS) Could Surge 35%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 30.00% and 14.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 20.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?